Policy Recommendations
Joint recommendations towards fair prices of medicines in Europe – July 2020
Submission to EU Pharmaceutical Strategy Consultation – June 2020
Joint Position Paper on Medicines Shortages & Amendments to INI on Shortages – April 2020
Access to Treatment – A Core Component of ECL’s Vision for Europe’s Beating Cancer Plan (pg 12-18) – February 2020
ECL submission to a public consultation on EMA Regulatory Science 2025 – June 2019
Position Paper on the outcomes of WHO resolution on ‘Improving the transparency of markets for medicines, vaccines and other health products’– June 2019
ECL comments within the EU Ombudsman’s inquiry OI/7/2017/KR – Public consultation – December 2018
LET’S TALK ACCESS! White Paper on Tackling Challenges in Access to Medicines – October 2018
ECL analysis on CAR T-Cell Therapies pricing – June 2018
ECL position paper on European Cooperation on Health Technology Assessment (HTA) – June 2018
Letters to Decision-Makers
Letter to European ministers of health in support of Italian draft resolution on transparency in pricing of medicines, vaccines and health technologies – May 2019
Joint Open Letter to the European Commission on investigation of root causes of medicine shortages – May 2019
Letter to national ministers of health on the role of pricing transparency and inter-governmental knowledge-sharing in access to affordable medicines – December 2017
Letter to Commissioner Vestager on the role of EU competition policy in equal access to Medicines – February 2017
Press Releases & Statements
ECL & EORTC joint statement on the judgments of the CJEU in Cases C-175/18, C-178/18 P
PTC Therapeutics International v EMA – January 2020
Publication of Let’s Talk Access White Paper – October 2018
Reaction to BMJ Study on efficacy of cancer medicines – October 2017
Infographics & Visuals
ECL Recommentdations for European HTA Cooperation
ECL Access to Medicines Task Force Declaration of Intent